Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
Infect Agent Cancer. 2013 Dec 2;8(1):46. doi: 10.1186/1750-9378-8-46.
Poly(ADP-ribose) polymerases (PARPs) comprise of a large family of 17 proteins encoded by various genes which participate in genome maintenance, apoptosis, inflammatory responses and the regulation of gene expression programs. PARP inhibitors, as therapeutic agents, come into play acting on both PARP 1 and PARP 2. These drugs seem to target tumor cells in a moment of vulnerability when they are undergoing DNA repair. In the past few years this class of anti-cancer drug has been discovered to show a promising niche in the clinic.
聚（ADP-核糖）聚合酶（PARPs）是由多个基因编码的 17 种蛋白组成的大家族，参与基因组维护、细胞凋亡、炎症反应和基因表达程序的调控。PARP 抑制剂作为治疗药物，同时作用于 PARP1 和 PARP2。这些药物似乎针对的是正在进行 DNA 修复的肿瘤细胞的脆弱时刻。在过去的几年中，这类抗癌药物在临床上已经显示出了很有前途的应用前景。
